Recovery of therapeutic proteins from inclusion bodies: problems and process strategies
The formation of inclusion bodies in strains of genetically engineered Escherichiu coli has been reviewed recently [ 1-41. This article addresses the consequences of selecting such a system on downstream strategies for the production of protein therapeutics.
Recovery
The initial recovery of product in the form of inclusion bodies has many attractive process features which have been exploited by the biotechnology industry. The product, being sequestered in a near homogeneous state in dense granules of tight size distribution, may be recovered at high purities on a multi-kilogram scale by cell disruption followed by centrifugation [ 5-61. Soluble cellular components may be depleted by cycles of centrifugation and resuspension in buffer, leaving cell debris and associated membrane-bound components as the major Contaminants of inclusion body preparations. Some of these membrane proteins in the debris can be removed from the insoluble inclusion body product by selective extraction using buffers such as Triton X-l00/urea, originally developed as general methods for solubilizing membrane proteins. Alternatively, the density difference between cell debris and inclusion body granules can be exploited by differential centrifugation in sucrose buffers, inclusion body material being collected in the solids discharge of the centrifugal separator and cell debris rejected in the supernatant. Using these methods large quantities of highly enriched recombinant product have been processed routinely.
The requirement for the removal of cell debris and the soluble constituents of the host is not necessarily obligatory, especially when accumulation levels of > 50% total cell protein have been achieved. Cell breakage by high pressure homogenization and the subsequent centrifugation operations are expensive in terms of fixed capital costs and energy consumption. The alternative strategy of recovering the inclusion body protein by directly solubilizing the cell paste in a strongly denaturing solvent, such as 8 M-guanidinium hydrochloride has therefore been advocated by some workers [7] . The choice may sometimes be determined more by constraints downstream than by the economics of recovery. For example, the recovery of renatured foot and mouth disease virus VPI coat protein, expressed in E. coli inclusion body fractions, is reduced by the presence of high molecular mass cellular components [ 8 ] and many process schemes employ an initial purification step before the removal of the solubilizing solvent [9, lo].
Most of the commonly used solubilizing agents, guanidine hydrochloride, acid or alkaline buffers and ionic detergent, reduce the choice of these initial pre-refolding purification steps to gel filtration. Urea solvents have found favour as solubilizing agents because their use permits consecutive subtractive ion-exchange chromatography, thereby removing nucleic acids, phospholipids and electronegative contaminant proteins from the process stream.
The major contaminants found in inclusion body preparations are peptidoglycans, lipids, nucleic acids, lipopolysaccharide and membrane-associated proteins. Although most of these components will dissolve under the harsh conditions often required to solubilize inclusion bodies, these substances are often poorly soluble under renaturing conditions and the bulk will precipitate without influencing the refolding of the recombinant product. The process stream may then be enriched further by centrifugation and filtration.
Refolditig
The refolding of proteins from the denatured state is both a problem of fundamental scientific interest and one of immense commercial significance. Refolding yields are often low and decrease in approximate proportion to increased molecular mass. This constraint can make the inclusion body production route commercially non-viable in itself and many groups have searched for alternative, less productive host/ vector systems to circumvent the inclusion body problem entirely. In the case of interleukin 2, the protein may be extracted in a buffer 15"A, (v/v) acetic acid] which does not disrupt the native state [ 1 I ] , solubilization and refolding presumably occurring during the same unit operation. Normally, efficient solubilization results in the complete disruption of all conformational structure. Two strategies have been adopted for optimization of the refolding reaction which I will call the empiricist approach and the rationalist approach. The empiricist approach involves the screening of a large number of refolding conditions by varying buffer ion, pH, product concentration, time and dilution ratios. Obviously only a small subset of these variables can be evaluated and the criterion for success is usually the generation of a soluble product or the regain of biological activity. The empiricist approach has become quite sophisticated with the use of multiple solvents [ 121 and data interpretation using phase diagrams as suggested by Ahmed & Bigelow [13] . The rationalist approach involves a detailed study of the conditions which promote refolding of the purified protein. It is then assumed that the protein denatured during inclusion body solubilization will refold under the same conditions. The use of purified protein enables a variety of spectroscopic techniques to be brought to bear. In its simplest form, the rationalist approach identifies those conditions which simultaneously promote stabilization of the native state while retaining sufficient denaturing potential to maintain unfolded and partially refolded intermediates in solution [ 141.
The formation of disulphide bridges may or may not be a prerequisite for recovery of a near-native tertiary structure. Some proteins such as reduced bovine growth hormone have been exposed to mildly denaturing solvents and poised in a near native state before oxidation and the completion of refolding [ 151. Other proteins maintain no stable tertiary structure without the formation of the correct disulphide contacts. Granulocyte macrophage colony stimulating factor shows no native tertiary structural features by near-u.v. circular dichroism on reduction of the two disulphides. However, far-u.v. circular dichroism detects near native levels of helical secondary structure [ 161. It was established by transverse urea gradient-gel electrophoresis that the oxidized protein has an unfolding transition at 5 M-urea and that the tertiary structure is stable in 3 M-urea. Thiol oxidation in the latter urea concentration led to a species with native near-u.v. circular dichroism. A purification scheme involving solubilization and refolding of inclusion body protein was optimized successfully using these conditions, which had been predicted by physical analysis of the purified protein [ 171.
As the disulphides formed during the first phase of protein folding may be non-native and several cycles of reshuffling of compact partially folded intermediates may be necessary, one approach has been to oxidize disulphides under denaturing conditions, remove covalent aggregates by gel filtration and then dilute the product into non-denaturing buffer [ 181. Collapse of the unfolded protein into a compact 'molten DOWNSTREAM PROCESSING 23s globule' which then rearrangcs to the native state may explain why these mcthods give risc t o high yields o f correctly folded protein with a minimum of mismatched disulphide-bonded species.
It is clear that the implications of current protein folding theory have already had an impact on the downstream processing strategies and it is to be hoped that refinements in theory will lead t o progress and application in large-scale use.
Further p i i i f i c~i i i o r i
Once refolded. the ovcrall strategy for purification of inclusion body protein is the same as for all proteins: differences in physical properties between the product and its contaminants are identified analytically and separation methods chosen which exploit these differences maximally. For example, many of the contaminating proteins found in E. coli inclusion bodies are residual solubilized membrane proteins and possess hydrophobic transmembrane structural motifs in their structure. Inclusion body protein may, however. be quite hydrophilic in naturc and after refolding subtractive hydrophobic interaction chromatography can often effectively remove these contaminants from the process stream [ 191. Non-proteinaccous contaminants are often acidic in nature (nucleic acid, phospholipids, lipopolysaccharide) and can be removed by subtractive anion-exchange chromatography. T h e isoelectric point of the product can also have an cffect on the efficiency of this step. Many human recombinant products, e.g. interferon-y, have a p l > 7.0. As most of the proteins found in E. coli membranes have pls of < 7.0, subtractive anion-exchange chromatography at pH 7.0-8.0
can lead to purification t o homogcncity in a single step I 1' 91.
Similarly, many E. colz proteins are poorly soluble below pH 5.0 and, providing the product is acid stable, can be selectively removed by acid precipitation and centrifugation.
T h e refolding process will always generate levels of misfolded derivatives o f the product: covalent and non-covalent aggregates, mismatched disulphides and chemically modified forms. Covalent and non-covalcnt aggregates are usually sparingly soluble and on precipitation may be removed by centrifugation. However. these derivatives may be soluble or form virus-sizcd particles which must be either flocculated or precipitated on t o batch chromatographic matrices to aid their removal.
T h e refolding of interleukin 2 can lead to the trapping of non-native conformations through mismatched disulphides [ 201. These species are more hydrophilic than the native oxidized form and can be separated by reversed-phase h.p.1.c. both on the analytical and the preparative scale [ 1 11. Refolding of interleukin 2 also leads to contamination by a residual reduced form. This derivative is more hydrophobic than the oxidized native product and can also be separated by reversed-phase h.p.1.c. [ 2 1 1. T h e refolding of interferona2 gives rise to low-level contamination by species which contain thiol residues which are either oxidized t o cysteic acid o r contain disulphides mismatched to glutathione from the redox buffer employed in refolding [22] . In this case, the contaminants may be removed by reversed-phase h.p.1.c. or by acid precipitation at the appropriate protein concentration [23] .
C'oticliisioti
The exact mechanism triggering inclusion body synthesis has not been conclusively defined. It is clear. however. that the over-expression of heterologous proteins in a foreign intracellular milieu often leads to accumulation of protein in inclusion bodies. This protein is usually complctcly insoluble in non-dednaturing buffers and presumably contains molecules of reduced solubility trapped in some kind o f nonnative conformation. In the case of many protein therapeutics, this observation poses an important quality assurance question: given that the raw material accumulating is the wrong structure. how can one be certain that subsequent downstream separation operations will result in the native (and presumably least immunogenic) conformation? Natural sources of proteins of therapeutic interest are often limited and even when comparisons arc possible. the techniques of biophysical analysis are so imprecise that the question cannot be answered definitely.
Safety in the clinic, therefore, relies to a large extent on ;I combination of ( a ) selection of unit operations and process validation to ensure reproducible manufacture and ( h ) the choice of processing conditions which generate a product ol high biological potency and maximum solubility and stability.
